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Abstract 
Neurodegeneration affects specific subtypes of neurons in particular 
functional anatomic systems, causing a heterogeneous clinical and pathological 
expression. Signal transduction deregulation, alteration of calcium homeostasis 
along with quality control systems failing often contribute to, or even directly 
underline these neurodegenerative processes. Although their significance is still 
debated, protein aggregates or other atypical protein assemblies seem to be 
both the common feature and strongly implicated in disorders like 
spinocerebellar ataxias (SCAs), Huntington’s, Parkinson’s or Alzheimer’s 
disease.  The SCAs compose a group of heterogeneous genetic disorders both 
clinical and genetically, mainly characterized by progressive degeneration of the 
cerebellum. Clinically, the patients show imbalance, progressive gait and limb 
ataxia, dysarthria and dysphagia. Missense mutations in the brain-specific 
gamma isoform of protein kinase C (PKCγ) are the cause of spinocerebellar 
ataxia type 14 (SCA14), and have been shown to be prone to aggregation. 
SH-SY5Y cells were used to generate the cellular SCA14 models, and 
PKCγ expression was assessed through western-blot, real-time PCR (for 
mRNA expression) and immunocytochemistry. In order to study the influence of 
PKCγ proteolysis by calpains and macroautophagy activation on PKCγ 
aggregation, calpain inhibition was achived through calpastatin co-transfection, 
and mTOR inhibition by treatment with rapamycin. 
Here, we show the successful establishment and characterization of two 
cellular models for SCA14, one transient and another stably expressing both 
wild-type and mutant PKCγ. We demonstrate, for the first time, that calpain 
inhibition significantly reduces aggregate formation and increases cell survival, 
pointing to a role of PKCγ proteolysis in protein turn-over and aggregation. Our 
preliminary data also point for a wide role of rapamycin in PKCγ aggregate 
clearance, and further discuss the possibility of both these ameliorating effects 
being mediated and converge in autophagy activation, as well as the 
importance of the C1 regulatory domain in aggregate formation. 
 
Keywords: PKCγ, Aggregation, Calpain, Autophagy 
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Sumário 
A neurodegeneração afecta conjuntos particulares de neurónios em 
sistemas anatómicos e funcionais específicos, dando origem a uma expressão 
clínica e patológica heterogénea. A estes processos, estão muitas vezes 
associados ou mesmo subjacentes, fenómenos que envolvem desregulação da 
transdução de sinal, alterações na homeostase do cálcio assim como falha dos 
sistemas de controlo de qualidade. Embora, o seu papel e importância ainda 
sejam muito debatidos, os agregados proteicos e outros conjuntos atípicos de 
proteínas, são características comuns e fortemente implicadas em várias 
doenças como ataxias espinocerebolosas (SCAs), e doenças de Huntinton, 
Parkinson e Alzheimer. As SCAs compreendem um grupo heterogénio de 
doenças genéticas tanto do ponto de vista clínico como genético, 
characterizadas  degeneração progressiva do cerebelo. Clinicamente, os 
doentes apresentam desequilíbrio,  ataxia progressiva da marcha e dos 
membros, disartria e disfagia. Mutações pontuais na isoforma gama da 
proteína cinase C (PKCγ), causam ataxia espinocerebolosa do tipo 14 
(SCA14), tendo já sido demonstrado que têm a capacidade de agregar. 
 A linha SH-SY5Y foi utilizada para gerar modelos celulares de SCA14, e 
a expressão da PKCγ foi avaliada através de western-blot, PCR em tempo real 
(para expressão de mRNA) e imunocitiquímica. Para estudar a influencia da 
proteólise da PKCγ pelas calpaínas, e a activação da macroautofagia sobre a 
agregação da PKCγ, foram realizadas co-transfecções com calpastatina e o 
mTOR foi inibido através do tratamento com rapamicina. 
 Aqui, mostramos a caracterização de dois modelos celulares para 
SCA14, um com expressão transiente e outro com expressão estável de PKCγ 
normal e mutada. Pela primeira vez, demonstramos que a inibição das 
calpaínas leva a uma redução significativa da formação de agregados, 
aumentando a sobrevivência celular, o que aponta para um papel importante 
da degradação da PKCγ no turn-over proteico e agregação. Os nossos dados 
preliminares também apontam para um efeito alargado da rapamicina sobre a 
remoção dos agregados, sendo que vamos mais além, e discutimos a 
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possibilidade de ambos os efeitos serem mediados, e convergirem, na 
activação da autofagia, assim como a importância que o domínio regulador C1 
tem, na formação de agregados. 
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1. Introduction	  
 
1.1. Neurodegeneration 
As a result of an increased life span, neurodegenerative disorders are 
the current major contributors to disability and disease, posing as such, a major 
concern for both healthcare practitioners and research scientists of the 21st 
century [1].  
Neurodegeneration affects neuronal activities at different levels. It can 
disrupt molecular pathways, synapses, neuronal subpopulations and local 
circuits in specific brain regions, as well as higher-order functional anatomic 
systems, causing a heterogeneous clinical and pathological expression. 
Abnormal network activities may result in a vicious cycle, further impairing the 
integrity and functions of neurons and synapses, for example, through aberrant 
excitation or inhibition. Among others, excitotoxicity, inflammation and oxidative 
stress are some of the mechanisms that may be involved in these diseases. 
Progressive neuronal loss is the hallmark of neurodegenerative disorders, 
however some neurological impairment may be a reflection of dysfunction 
rather than neuronal loss [2]. 
Here, abnormal protein assemblies seem to play an important role, by 
triggering vicious cycles of aberrant neuronal activity, compensatory alterations 
in neurotransmitter receptors and related signalling pathways, that eventually 
lead to synaptic deficits and disintegration of neural networks, which in turn, 
result in neuronal function failure [2]. 
Another feature of these disorders is the dynamic chronicity, which is 
intimately related with the “degeneracy” of the neuronal system. This chronicity 
allows the brain to engage in compensatory mechanisms which include, for 
example, increasing neuronal activity in the remaining undamaged region or 
drawing other brain regions into the network that are otherwise not usually 
involved. Nonetheless, over time, these compensatory mechanisms ultimately 
fail, and some of them, may even turn out part of the problem by becoming 
pathogenic themselves [2]. 
	   2	  
Although their significance is still debated, protein aggregates or other 
atypical protein assemblies seem to be both the common feature and strongly 
implicated in several neurodegenerative disorders, like spinocerebellar ataxias 
(SCAs), Huntington’s, Parkinson’s or Alzheimer’s disease [2,3]. These 
disorders, also known as proteinopathies, include various types of aggregates 
with different cellular localization, where the proteins can be predominantly 
aggregated in the cytosol, in the nucleus, in the endoplasmic reticulum, or be 
secreted and accumulate extracellularly [4]. Although, generally, the large 
aggregates themselves are not considered toxic, it appears that the capacity to 
aggregate correlates with toxicity. 
 
 
1.2. Spinocerebellar ataxias 
The dominantly inherited ataxias, also known as spinocerebellar ataxias 
(SCAs), comprise a heterogeneous group of neurodegenerative disorders 
mainly characterized by slowly progressive cerebellar degeneration, often 
accompanied by changes in the brainstem or other brain regions. Clinically 
SCAs show progressive cerebellar ataxia of gait and limbs, associated or not 
with ophthalmoplegia, pyramidal and extrapyramidal signs, dementia, 
pigmentary retinopathy and peripheral neuropathy [5,6]. Epidemiological data 
indicates that the SCAs prevalence varies between 1 and 5/100,000 inhabitants 
[6], with age at onset between the third and fifth decade of life, although there 
are cases where either earlier or later onset has also been observed [5].  
Currently, SCAs can be grouped in three major genetic classes.  The first 
group includes SCA1-3, SCA6, SCA7, SCA17 and dentatorubropallidoluysian 
atrophy (DRPLA), which together with Huntington disease and spinobulbar 
muscular atrophy compose the polyQ disorders. They are caused by CAG 
repeat expansions that encode a pure repeat of the amino acid glutamine in the 
disease protein, that together account for more than 50% of all cases. The 
second group – non-coding repeat expansion ataxias – includes SCA8, SCA10 
and SCA12 that are due to repeat expansions falling outside of the protein-
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coding region of the respective disease genes. Finally, the third group 
comprises SCAs that instead of being caused by repeat expansions are due to 
conventional mutations (missense, nonsense, deletions, insertions, duplications 
or splice site mutations) in specific genes. The overall most important common 
feature is, perhaps, the pattern of neurodegeneration that is reflected in the 
clinical traits, although their distinction heavily relies on the extracerebellar signs 
of brain involvement [7]. 
In this context, understanding the pathogenetic mechanisms underlying 
neurodegeneration in spinocerebellar ataxias would help to identify potential 
therapeutic targets and ultimately facilitate drug discovery [5]. 
 
 
1.2.1. Spinocerebellar ataxia type 14 
Spinocerebellar ataxia type 14 (SCA14), first described in a Japanese 
family by Yamashita and colleagues (2000) [8], is an autosomal dominant 
neurodegenerative disorder characterized by slowly progressive cerebellar 
dysfunction including gait and limb ataxia, dysarthria and abnormal eye 
movements, with an age at onset ranging from early to late adulthood [9]. Later, 
in 2003, Chen and colleagues associated for the first time mutations in the 
gamma isoform of protein kinase C (PKCγ) with dominant non-episodic 
cerebellar ataxia [10]. SCA14 is usually compatible with a normal life span, 
although affected individuals can become wheelchair-bound later in life [7]. 
Since PKCγ has a somewhat well characterized normal function, in 
integrating signal transduction, abnormalities in these pathways seem to be 
central for this pathology. 
Although deletion of PKCγ (knock-out) produces apparently normal 
viable mice (mild phenotype), behavioral analysis revealed that these animals 
have slight ataxia, modest learning and memory impairment [11], along with 
some motor incoordination [12] that may relate to defects in the elimination of 
multiple climbing fiber innervation of Purkinje cells [13], and even though 
synaptic transmission appears to be normal, long-term potentiation (LTP) is 
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impaired [11], and they also show reduced pain sensitivity [14]. In contrast, the 
recently described PKCγ H101Y transgenic mouse model, presents a more 
severe phenotype when compared to the previous model [15]. 
Mutant PRKCG gene products are less stable than normal protein, 
leading to abnormal activation patterns, altered membrane targeting and 
enhanced activity [9,16]. Actually, more than 80% of the disease-causing 
mutations that have been previously described are in the regulatory portion of 
PKCγ, more precisely in the C1 domain, and furthermore, no truncating 
mutations have been found so far, so that it is speculated that the SCA14 
phenotype resulted from gain-of-function mechanisms rather than 
haploinsufficiency [17]. However, other authors have shown that gain-of-funtion 
may only be part of the mechanism and that haploinsufficiency and loss-of-
function mechanisms may also contribute to cell death in SCA14 [18,19]. 
 
 
1.3. The PKC family 
The PKC family, a class of highly regulated Ser/Thr protein kinases 
typically localized near the cellular membrane, is arising as an important player 
for higher-level signal organization control. This family of largely conserved 
proteins represents about 2% of the human kinome [20], and not only can they 
be recruited to scaffolds along other transducers, but can also control the 
behavior of the scaffolded complexes, through the promotion of their 
assembly/disassembly or subcellular localization without necessarily being part 
of the complex itself and meanwhile be subject to regulation through 
recruitment themselves [21,22].  
This complex family ranges from a single isoform in budding yeast (S. 
cerevisiae) to 5 isoforms in C. elegans and 12 in mammals [20,23]. 
Due to biochemical properties and sequence homology, PKC isoforms 
are divided into four subfamilies: conventional PKCs (also called classical), 
novel PKCs, atypical PKCs and PKC-related kinases (PKNs) [23,24]. 
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Conventional PKCs (cPKCs) are the most well known and studied group, 
comprising the α, βI, βII and γ isoforms. This group is activated through DAG 
and phospholipid binding to their C1 domains, that shifts the affinity of this 
protein for Ca2+ into its physiological range, thus binding phospholipids to their 
C2 domains in a Ca2+-dependent manner [25]. The tumor-promoting phorbol 
ester PMA (or TPA) is also a cPKC activator, that eliminates the requirement for 
DAG and increases the affinity for Ca2+ [26].  
The novel PKCs (nPKCs) group includes the δ, ε, η and θ isoforms that 
differ from the previous ones by being Ca2+-insensitive, though they can still be 
activated by DAG/phorbol esters and phospholipids.  
The atypical PKCs (aPKCs), ε and ι, are both Ca2+ (like the novel) and 
DAG/PMA-insensitive [27], although they are instead allosterically activated by 
interaction with the partitioning defective 6 (PAR6)-CDC42 complex, which is 
involved in determining cell polarity [28]. 
The last group consists of at least three known isotypes of PKC-related 
kinases (PKNs1-3), and similar to aPKCs they are both insensitive to Ca2+ and 
DAG/phorbol esters [29], while having an allosteric mode of regulation through 
binding of active RhoA-GTPases [30,31].  
In addition to these specific inputs, other regulatory processes influence 
the function of PKCs. These include the covalent modification (more precisely 
phosphorylation) of PKCs and their interaction with specific binding partners, 
which can modulate the requirements for allosteric inputs or in some cases 
bypass them all together, as seen for some scaffold interactions [21]. 
The different combinations between the conserved kinase domain and a 
series of differentially activated regulatory domains confer a modular nature to 
PKC that allows for its action to have spatial and temporal resolution. It also lets 
PKC activity to be directed by various inputs, including localized (membrane 
limited) second messenger production and interaction with membrane – 
anchored small G proteins, scaffolds and other accessory proteins. As a result 
the PKC family is centrally involved in the spatial control of signal transduction 
in cells [20]. 
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Assigning specific functions to several members of this kinase class has 
been a challenging task not only because of its sizeable number, but also due 
to its large overlapping substrate specificities. Nevertheless, mouse knockout 
models have suggested a certain degree of redundancy, even though 
increasing evidence proposes individual, non-redundant, although subtle roles 
for several of these family members [32]. 
 
 
1.3.1. PKC building blocks 
All members of the PKC superfamily share basic structural features: a 
divergent N-terminal regulatory domain linked by a hinge region to a conserved 
C-terminal kinase domain (Figure 1) [20]. The regulatory regions of these 
kinases have two functions: to bind to the plasma membrane or other cellular 
targets, and to inhibit the active site of the enzyme. The C-terminal region 
functions as the substrate binding site and phosphor-acceptor/donor site [33].  
 
Figure 1 – A schematic representation of the domain structure of the mammalian 
protein kinase C (PKC) family. The mammalian PKCs can be divided into four 
structurally and functionally distinct subgroups according to their regulatory domains. 
These are the classical isoforms (cPKCs), novel isoforms (nPKCs), atypical isoforms 
(aPKCs) and the PKC-related Kinases (PKNs). Between them, the N-terminal 
regulatory portions have a divergent distribution of the smaller domains: 
Pseudosubstrate, C1, C2, PB1 and HR1. Adapted from Rosse et al (2010) [20]. 
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1.3.2. PKC expression profile 
Soon after the various PKCs were identified it became clear that these 
kinases have tissue-specific patterns of expression, although within a given 
tissue they may vary depending on its developmental stage. Again, this points 
towards the great importance of certain combinations of PKCs and that they are 
necessary in order to guarantee a specific order of events that in turn lead to, 
and help maintain, the characteristics of a given tissue [24]. For example, 
PKCγ, a conventional isoform, is expressed mainly in brain cells, neuronal 
tissues, retina, and lens. The ubiquitous α isoform as well as all others, except 
λ, are also present in neuronal tissue. In epidermis, α, δ, ε, η and ζ are co-
expressed and participate in the complex differentiation and cell death program 
which exists in skin tissue. In the heart, PKCα, β, δ, and ε are expressed while 
the γ isoform is absent [33]. 
 
 
1.3.3. PKC life cycle: control by phosphorylation 
The protein kinase C family is part of a larger ABC protein kinases 
superfamily that also includes protein kinase A (PKA) and protein kinase B 
(PKB, also known as Akt). Maintaining the latent state of protein kinase C (PKC) 
isoforms requires for the catalytic domain to be in a form that can bind protein 
substrates and also undergo auto-inhibition by pseudosubstrate binding [33]. 
Figure 2 summarizes the life cycle of PKCs. 
Newly synthesized PKC molecules associate with the membrane in an 
open conformation in which the pseudosubstrate is not bound to the kinase 
active site. Because the pseudosubstrate can mask the activation loop 
sequence, this open conformation is critical for the next steps of PKC 
processing. In the “open” form, the unphosphorylated C-terminus is also 
exposed, providing a docking site for phosphoinositide-dependent kinase-1 
(PDK-1) [34].  
PDK-1 phosphorylates the activation loop, and is released from the C-
terminal docking site (rate limiting step), thus exposing sites on this segment for 
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phosphorylation. Afterwards, through an intramolecular autophosphorylation 
mechanism the turn motif and hydrophobic motif are phosphorylated. 
Phosphorylation of these C-terminal sites results in a number of key 
conformational changes that lock PKC into a more stable, protease- and 
phosphatase-resistant conformation, releasing the substrate-binding cavity to 
bind the pseudosubstrate sequence [34]. In fact, mTORC2 complex also 
participates in this final step by promoting phosphorylation of the turn and 
hydrophobic motif sites in the C-terminal tails of these kinases (see Figure 2 
step 1) [35]. 
 
Figure 2 – Model showing the life-cycle of PKC, from its biosynthesis to its eventual 
down-regulation. Reproduced from Newton (2009) [36]. 
 
It is the now fully “mature” (phosphorylated) species of PKC that 
translocate to membranes. In cells, for both conventional and novel PKCs, the 
bulk of these enzymes is in the mature form and can be found in the cytosol 
[34]. 
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PKC is activated when second messengers and/or allosteric effectors 
bind to its regulatory domain, usually at the plasma membrane. This disrupts 
the docking of the regulatory kinase domain, which displaces the bound 
pseudosubstate region from the active site, allowing the activation of PKC (see 
step 2) [37]. 
The active species of PKC are highly sensitive to dephosphorylation, and 
are usually found in the detergent-insoluble fraction of cells where they 
eventually suffer proteolysis (see step 3). A study has shown that the 
dephosphorylated turn motif provides a specific binding site for the molecular 
chaperone Hsp70 that prevents the association with the detergent-insoluble cell 
fraction. This dephosphorylation-dependent binding of Hsp70 stabilizes PKC 
and allows it to become rephosphorylated and cycle back into the pool of 
functional PKC [38]. 
Note that the phosphorylation step is constitutive, and the translocation 
and dephosphorylation are agonist-evoked. PKC that is not rescued by Hsp70 
accumulates in a detergent-insoluble cell fraction, is ubiquitinated by E3 ligases 
such as the recently discovered RINCK and then degraded [36].  
 
 
1.3.4. PRKCG/PKCγ  
The human PRKCG gene maps to the 19q13.4 locus, and comprises 18 
exons along an approximate length of 25.44 kb [39]. The full-length 3.133 kb 
transcript encodes PKCγ, a protein with 697 amino acids mostly expressed in 
the cerebellum, hippocampus and cerebral cortex [39]. During rat development, 
PKCγ expression is low at birth and progressively increases up to 2-3 weeks (in 
contrast to other conventional isoforms) which suggests an important role of 
PKCγ in synaptic formation (Figure 3) [40].  
It has been demonstrated that several neuronal functions, including long 
term potentiation (LTP) and long-term depression (LTD), specifically require this 
kinase. In hippocampal pyramidal cells, PKCγ is predominantly localized in the 
postsynaptic dendrites and activation of postsynaptic PKC appears to be 
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necessary for the induction of LTP. Furthermore, PKCγ knockout mice only 
have a discrete phenotype of slight ataxic gait although LTP formation seems to 
be impaired [41]. PKCγ activation in the CA1 region participates in postsynaptic 
plasticity associated with spatial experiences and learning [42]. 
Figure 3 – Possible functions of PKCγ in the nervous system. Adapted from Saito & 
Shirai (2002) [41]. 
 
PKCγ directly interacts with, and phosphorylates, the GluR4 alpha-
amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor (AMPAR) subunit, 
targeting these receptors towards cell surface expression [43]. Activation of 
type I metabotropic glutamate receptors (mGluR) leads to PKCγ activation that 
in turn directly phosphorylates Ser890 of the N-methyl-D-aspartate receptor 
(NMDAR) [33]. In response to EGF stimulation, PKCγ also regulates Myosin IIB 
phosphorylation and cellular localization [44]. 
Other cases in which PKCγ is important for neural function are related to 
sensitivity to alcohol, opiates, and pain. Ethanol exposure selectively alters 
PKCγ translocation to GABAA receptors, which regulates trafficking of the 
GABAAα1 subunit containing receptors [45].  
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1.4. The calpain system 
The calpain family comprises a group of calcium-regulated cysteine 
proteases that were discovered more than 40 years ago. Since then, they have 
been implicated in a wide range of pathologic conditions including 
neurodegenerative diseases, although the precise mechanism of calpain-
mediated neuronal injury is still unclear [46].  
From the 15 members found in humans (with tissue specific patterns of 
expression), only the catalytic subunits 1, 2, 3, 5, and 10, and two small 
regulatory subunits are found in the brain [47]. Despite several attempts to 
predict a preferential sequence for calpain cleavage it seems that this protease 
does not act through primary structure recognition, but instead through 
identification of secondary (or tertiary) structure, thereby difficulting substrate 
identification by making it unpredictable. A number of different proteins have 
been described and a long list of known calpain substrates is extensively 
reviewed in Vosler et al (2008) [48].  
Calpains function as cytoplasmatic cysteine proteinases, regulatory 
enzymes transducing intracellular Ca2+ signals into the controlled proteolysis of 
their substrates. Because of the presence of numerous downstream targets in a 
variety of signaling pathways, calpains are speculated to play important roles in 
cytoskeletal remodeling, cell differentiation, apoptosis, necrosis, embryonic 
development, and long-term potentiation in the central nervous system [46]. An 
example is the limited proteolytic cleavage of protein kinase C (PKC) into a 
permanently active fragment (PKM) [49]. 
The most abundant and well-characterized brain calpains are the µ and 
m isoforms. Both these proteases exist as heterodimers, each with a distinct 78-
80 kDa catalytic subunit and a 29 kDa common regulatory subunit [47].  
Both isoforms interact with Ca2+, and in its absence, the catalytic triad is 
pulled apart. µ-calpain has a less dramatic separation of the catalytic residues 
and one of the calcium-binding regions is more flexible, which probably explains 
the primary biochemical distinction made between these two forms, namely with 
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µ-calpain requiring micromolar Ca2+ for activation whereas m-calpain requires 
millimolar levels [46,47]. 
Calpains can be activated by many apoptotic and necrotic stimuli, in 
particular, those that alter Ca2+ homeostasis. Furthermore their activation often 
lies upstream of caspase activation [50]. 
In addition to the various protease isoforms, the calpain system includes 
a single endogenous inhibitor – calpastatin. In humans, there have been 
described various calpastatin isoforms, that result from alternative splicing of a 
single gene (CAST) [39]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Schematic diagram showing the domain structure of calpastatin. a, 
Calpastatin is an elongated protein that contains several independent inhibitory 
domains (CIDs). The larger isoform of calpastatin (contains four CIDs) also has a 
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terminal L-domain that anchors the protein to cell membranes. Each CID is composed 
of three regions, A–C, that interact with different calpain domains. b, Calpain crystal 
structure scheme (m-calpain) in complex with calcium and calpastatin CID domains. 
Calpain’s four catalytic subunit domains (dI to dIV) are shown in blue, and its regulatory 
subunit domain dVI is shown in green. When m-calpain binds to calcium, it adopts a 
compact, active conformation in which dIII moves toward dII, forming the active site 
(red). The A region of the CID associates with dIV, whereas the C region binds to dVI. 
The B region wraps around the remaining subunits, blocking the active site, meanwhile 
looping away from it to avoid being cleaved by the enzyme. Reproduced from Mellgren 
(2008) [51]. 
 
 
Each calpastatin molecule contains four regions, or calpain inhibitory 
domains (CIDs I–IV), that interact with calpains and block their activity (Figure 
4a), therefore this repeated domain structure allows calpastatin to 
simultaneously inhibit four calpain molecules (one per each CID) [46]. In turn, 
each of the CIDs is subdivided into three regions (A, B and C), responsible for 
calpain binding [51]. In solution, calpastatin exists in a mostly unraveled 
conformation, that allows its four identical domains to bind, in theory, four 
calpain molecules [47].  
Curiously, calpastatin itself can be a substrate for calpains (which 
cleaves in the disordered regions between CIDs), nevertheless, the resulting 
proteolytic fragments seem to retain the inhibitory function [48]. However, the 
most surprising thing, is that calpastatin – largely disordered on its own – blocks 
calpain activity with an unfolded protein portion and despite this risky action, is 
fine-tuned to generate a local structural motif (loops away from active cleft) that 
protects it from an attack when attached to its calcium-bound substrate (Figure 
4b) [52]. 
 
 
1.5. Autophagy 
In eukaryotic cells, the two main routes for protein and organelle 
clearance are the ubiquitin-proteasome and autophagy-lysosome pathways [3]. 
The proteasome, comprises a barrel-shaped multi-protein complex that 
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predominantly degrades short-lived nuclear and cytosolic proteins, that also 
plays an important role in degrading misfolded proteins in the endoplasmic 
reticulum [53]. 
Substrates such as protein complexes and organelles can be degraded 
by lysosomes. This degradation in bulk is largely mediated by macroautophagy, 
involving the formation of double-membrane-bounded structures. 
Degradation of intracellular components in lysosomes is generally known 
as autophagy, and although the first description, by Christian de Duve, occurred 
more than 50 years ago, only recently this process has captured the interest of 
the scientific community, in particular, concerning its role in neurodegeneration. 
Currently we know three different mechanisms for delivery of autophagic cargo 
to lysosomes that coexist in the majority of mammalian cells: macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA) [54]. In the context 
of this thesis we will focus on macroautophagy and CMA.  
 
 
1.5.1. Macroautophagy 
In macroautophagy, whole regions of the cytosol are sequestered and 
delivered to lysosomes for degradation. This cargo sequestration occurs in the 
autophagosome, a double membrane vesicle that forms through the elongation 
and sealing of a de novo generated membrane. Furthermore, autophagy 
studies in yeast, revealed that a series of Atg protein conjugating steps, 
remarkably similar to the ubiquitin conjugating system, precede membrane 
nucleation and elongation. In fact, this process requires two Atg conjugating 
systems and two kinase complexes [55]. In mammals this limiting membrane, 
also called phagophore, originates from a tightly controlled series of interactions 
between more than 10 different proteins.  
In many cellular settings, the first regulatory process involves the de-
repression of the mTOR Ser/Thr kinase (Figure 5, step1), which inhibits 
autophagy by phosphorylating autophagy protein-13 (Atg13), leading to the 
dissociation of Atg13 from a protein complex containing Atg1 kinase and Atg17, 
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thus attenuating Atg1 kinase activity. When mTOR is inhibited, re-association of 
dephosphorylated Atg13 with Atg1 stimulates its catalytic activity and induces 
autophagy. Another initial step of vesicle nucleation is the activation of 
mammalian Vps34, a class III phosphatidylinositol kinase (PI3K), which 
depends on the formation of a multiprotein complex containing beclin-1, UV 
radiation resistance associated gene (UVRAG) and a myristylated kinase 
(Figure 5, step2) [55,56]. 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 5 – Autophagy starts with the stepwise engulfment of cytoplasmic material 
(cytosol and/or organelles) by the phagophore, which sequesters material in double-
membraned vesicles named autophagosomes. In mammals this limiting membrane 
originates from a tightly controlled series of interactions between more than 10 different 
proteins and requires two kinase complexes and two Atg conjugating systems (steps 1-
2 and 3-4 respectively). Autophagosomes undergo maturation and fuse with lysosomes 
to create autolysosomes (steps 5 and 6), where the inner membrane and luminal 
content of the autophagic vacuoles, is degraded by lysosomal enzymes. 
Pharmacological inhibitors and small interfering RNAs that are capable of inhibiting 
distinct steps of this process are shown (red blocking arrows). Reproduced from Maiuri 
et al (2007) [56]. 
 
Two ubiquitin-like conjugation systems are part of the vesicle elongation 
process (Figure 5, step3). One pathway involves the covalent conjugation of 
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Atg12 to Atg5, mediated by Atg7 (E1-like enzyme) and Atg10 (E2-like enzyme). 
The second pathway involves the conjugation of phosphatidylethanolamine 
(PE) to LC3 through sequential action of Atg4 (protease), Atg7 (E1-like enzyme) 
and Atg3 (E2-like enzyme) that ultimately leads to conversion of the soluble 
LC3 (LC3-I) into the autophagic-vesicle-associated LC3-II. In later stages, 
autophagosomes undergo maturation by fusion with lysosomes to create 
autolysosomes (Figure 5, steps 5 and 6), where lysosomal enzymes degrade 
the inner membrane and luminal content of the autophagic vacuoles [55,56].  
In neurons, although elusive, constitutive macroautophagy is a quite 
active process that has been shown to be both indispensable and exceptionally 
efficient at eliminating autophagosomes and later stage autophagic vacuoles 
once they are formed [57]. 
 
 
1.5.2. Chaperone-mediated autophagy 
In contrast to both macro- and microautophagy, chaperone-mediated 
autophagy (CMA) does not require cargo delivery through the formation of 
intermediate vesicles, membrane fusion or deformation of any kind. Instead, the 
substrates are translocated from the cytosol into the lumen directly across the 
lysosomal membrane, a process that is mediated by a translocation protein 
complex, which requires protein unfolding. Whereas this pathway cannot 
degrade organelles, it is extremely selective for a subset of cytosolic proteins 
which are transported one-by-one across the lysosomal membrane for 
degradation [58]. The molecular machinery responsible for this process is 
organized around three basic important principles: recognition of the substrate 
protein, mediated by the targeting signal and the complex of cytosolic 
chaperones that recognize it; the translocation complex at the lysosomal 
membrane, that binds and unfolds the substrate; and finally, translocation 
across the membrane [59].  
All CMA substrates contain in their amino acid sequence a pentapeptide 
motif biochemically related to KFERQ, known as the CMA-targeting motif, 
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shown to be necessary and sufficient for lysosomal degradation. To date, all the 
CMA targeting motifs adhere to the following characteristics: a pentapeptide 
flanked in either side by a Q residue and containing a positive residue (R or H), 
a negative (D, E), a hydrophobic residue (F, L, I or V) and being the additional 
residue positive or hydrophobic but never negative. These residues can 
organize in any order inside the sequence as far as the Q is in one of the sides 
[58]. It is estimated that 30% of cytosolic proteins have a KFERQ-like motif, and 
therefore in theory, might be degraded by CMA [59].  
In the cytosol, this pentapeptide is recognized by a group of molecular 
chaperones and co-chaperones, of which heat shock cognate protein of 70 kDa 
(Hsc70) is an important member. This chaperone, not only binds the KFERQ-
like motif targeting the CMA substrate to the lysosomal membrane, where it can 
interact with the CMA receptor, but it also likely facilitates substrate unfolding 
which is fundamental for the protein’s translocation into the lysosome. In order 
to complete substrate translocation, there is also a requirement for a lumenal 
form of hsc70 inside the lysosomes (lys-Hsc70) [60]. In addition, some recent 
studies propose that the carboxyl terminus of HSP70-interacting protein (CHIP), 
another cytosolic chaperone that contributes to the degradation of cytosolic 
proteins by the proteasome, also targets proteins for lysosomal degradation 
[61]. Another chaperone present in both sides of the lysosomal membrane is 
Hsp90, which is thought to participate in substrate unfolding and translocation 
complex stabilization [62].  
 The lysosome-associated membrane protein type 2A (LAMP-2A) is also 
needed for substrate translocation to occur, acting as a substrate receptor in an 
initial phase, and later, once it multimerizes, as a translocator complex. In 
contrast to Hsc70, which is often in excess in the cytosol, LAMP-2A levels at the 
lysosomal membrane are limited and subject of tight regulation, representing 
the rate-limiting constituent of CMA. This translocation complex is remarkably 
dynamic, undergoing continuous cycles of assembly/disassembly depending on 
substrate availability, an action that both Hsc70 and lysosomal lipid 
microdomains contribute to [59].  
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CMA is activated to its highest levels under stress conditions (inducible 
CMA), such as nutritional stress or starvation, and cellular stresses leading to 
protein damage [54]. Indeed, both macroautophagy and CMA often act in a 
synchronized or sequential manner. For instance, during starvation, 
macroautophagy is the first to be activated, and then, as starvation persists, 
cells switch from bulk degradation to CMA, which allows selective targeting of 
non-essential proteins for degradation in order to obtain the amino acids 
required for the synthesis of essential ones [63,64].  
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2. Objectives	  
The main goal of this work was to gain insights into aggregate formation, 
dynamics and clearance in a cellular model for spinocerebellar ataxia type 14.  
Specifically, we aimed to (1) generate a model for SCA14 in 
neuroblastoma cells; (2) characterize several PKCγ mutants regarding protein 
expression, aggregate formation and cell survival; (3) assess the role of PKCγ 
proteolysis by calpains in the dynamics of aggregate formation and cytotoxicity; 
and finally (4) investigate autophagy’s role in the clearance of PKCγ 
aggregates. 
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3. Material and Methods 
3.1. DNA constructs 
The N-terminal FLAG tagged human calpastatin cDNA (NM_173060.3) 
cloned in a pcDNA5 vector was kindly provided by Professor Carlos Duarte. A 
pEGFP-C1 vector with the cDNA for the human PKCγ (NM_002739.3), 
previously subcloned, was used to generate all mutants. 
 
 
3.2. Site-directed mutagenesis 
Eight PKCγ mutants (Table 1) were generated with the QuickChange 
site-directed mutagenesis Kit (Agilent Technologies) as per manufacturer’s 
instructions, using standard desalting-purified oligonucleotide primers (IDT), in a 
T-Gradient thermocycler (Biometra). In brief, and for each intended mutation, 
1,5 µg of plasmid DNA were added to a reaction mix containing 125 ng of each 
primer (forward and reverse, see table 1), 10x reaction buffer (to a final 
concentration of 10 mM KCl, 10 mM (NH4)2SO4, 20 mM Tris-HCl (pH 8.8), 2 mM 
MgSO4 0.1% Triton X-100 and 100 µg/mL BSA), 50 ng (10 mM) of a dNTP mix, 
250 U of PfuTurbo DNA polymerase and ddH2O up to a final volume of 50 µL. 
In order to amplify the mutant plasmids, all samples were denatured at 95ºC for 
30 sec, followed by 18 cycles comprising a cycle of denaturation at 95ºC for 1 
min, annealing at 65ºC for 1 min, and then an extension at 68ºC for 25 min. The 
amplified product was then incubated with 1000 U of Dnp I at 37ºC for 2 hours 
in order to degrade the methylated DNA template (non-mutated). 
Afterwards, XL1-Blue Supercompetent Cells (E. coli) (Agilent 
Technologies) were transformed by heat shock with 1 µL of Dpn I-treated 
sample reaction. Transformed bacteria were plated in selective LB-agar plates 
containing 50 µg/mL of kanamycin, and incubated overnight at 37ºC. Fresh 
selective liquid LB was inoculated with resistant colonies and incubated 
overnight with vigorous shaking, at 37ºC, for plasmid DNA extraction. Individual 
mutations were verified by direct sequencing of plasmid cDNA. 
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Table 1 - Primers used for site-directed mutagenesis of the wild-type pEGFP-PKCγ 
construct. 
PKCγ mutant 
(cDNA/protein) 
Forward/
Reverse  Primer Sequence 
c.122G>C / R41P Fw 5'-ACAAGTTCACCGCTCCCTTCTTCAAGCAGCC-3' 
 Rv 5'-GGCTGCTTGAAGAAGGGAGCGGTGAACTTGT -3' 
c.188G>T / G63V Fw 5'-GGTATCGGAAAGCAGGTCCTGCAATGTCAAGTC-3' 
 Rv 5'-GACTTGACATTGCAGGACCTGCTTTCCGATACC-3' 
c.301C>T / H101Y Fw 5'-ACGACCCCCGGAACAAATACAAGTTCCGCC-3' 
 Rv 5'-GGCGGAACTTGTATTTGTTCCGGGGGTCGT-3' 
c.303C>G / H101Q Fw 5'-CCCCGGAACAAACAGAAGTTCCGCCTGCATAG-3' 
 Rv 5'-CTATGCAGGCGGAACTTCTGTTTGTTCCGGGG-3' 
c.391T>C / C131R Fw 5'-TGTGCACCAGGGCATGAAACGCTCCTGCTG-3' 
 Rv 5'-CAGCAGGAGCGTTTCATGCCCTGGTGCACA-3' 
c.1081A>G / S361G Fw 5'-TGGTTCTAGGAAAAGGCGGTTTTGGGAAGGTGATG-3' 
 Rv 5'-CATCACCTTCCCAAAACCGCCTTTTCCTAGAACCA-3' 
c.1928T>C / F643L Fw 5'-CGCAGCGGCGAGAACCTTGACAAGTTCTTCAC-3' 
 Rv 5'-GTGAAGAACTTGTCAAGGTTCTCGCCGCTGCG-3' 
c.2075T>G / V692G Fw 5'-CACCAGCCCAGGGCCTGTGCCCG-3' 
 Rv 5'-CGGGCACAGGCCCTGGGCTGGTG-3' 
 
 
3.3. Plasmid DNA isolation 
The QIAprep® Miniprep kit (QIAGEN) was used, to isolate plasmid DNA 
from bacteria grown overnight in 5 mL LB medium with the appropriate selective 
antibiotic, according to manufactures’ instructions. In summary, bacteria were 
harvested from the culture medium by centrifugation at 3000 rpm for 10 min at 
room temperature and the supernatant was discarded. The pelleted bacteria 
were then re-suspended in buffer P1, containing 50 mM Tris-HCl (pH 8.0), 10 
nM EDTA and 100 µg/mL of RNase A. Cells were lysed (with both 
chromosomal DNA and proteins being denatured) in 200 mM NaOH and 1% 
SDS (Buffer P2). After centrifuging cell extracts at 13000 rpm for 10 min (room 
temperature), the supernatant was applied to the QIAprep spin columns, which 
were then centrifuged for 1 min. The columns were then washed with PB and 
PE buffers, with 1 min centrifugation after each addition. Any remaining wash 
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buffer was removed from the columns by one extra centrifugation (1 min). The 
spin columns were then incubated with EB (10 mM Tris-Cl, pH8.5) and the 
plasmid DNA recovered with a final 1 min centrifugation step. Plasmid DNA was 
quantified using NanoDrop 2000 (Thermo Scientific). 
 
 
3.4. Direct sequencing 
The different constructs were directly sequenced with Big Dye 
Terminator sequencing Kit (v1.1; Applied Biosystems) by adding to 1 µL of 
purified plasmid DNA, 2 µL of BigDye ready reaction mix, 0.5 µL of the 10 µM 
specific primer (Table 2) and ddH2O up to a final volume of 10 µL. Sequencing 
conditions were as follows: an initial denaturing cycle at 95ºC for 5 min, followed 
by 35 cycles of denaturation at 96ºC for 10 sec, annealing at 50ºC for 5 sec, 
and an extension at 50ºC for 4 min, performed in a T-Gradient thermocycler 
(Biometra).  
 
Table 2 - Primers used for direct sequencing of all pEGFP-C1-PKCγ and FLAG-CAST-
pcDNA5 constructs. 
Construct Primer ID Primer 
CASTF1 5'-GTGAGCAACCTGTGGTTCACG-3' 
CASTF2 5'-GCTCAGTCTGCAGGAGTGAC-3' 
CASTF3 5'-CCACTCCTGCCCAAAGAATCCC-3' 
CASTR1 5'-GCCTTTGGCTTGGACACTTCC-3' 
CASTR3 5'-CCCAGTGCCTCAAGGTAGG-3' 
FLAG-CAST-pcDNA5 
CASTR4 5'-CCGGAGGAGTTTGGGATGTG-3' 
PKCF1 5'-CCTTCTGCGACCACTGT-3' 
PKCF2 5'-GCAACGACTTCATGG-3' 
PKCF4 5'-GCTGTATGAGATGTTGG-3' 
PKCF5 5'-TCCACTCCACCTTCCAGACC-3' 
PKCR1 5'-CGCTCGGTGTGGTCCACA-3' 
PKCR2 5'-GCTGCAGTTGTCAGCAT-3' 
PKCγ-pEGFP 
PKCR3 5'-GGGAGACTTGATGTACC-3' 
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The sequencing product was then purified using DyeEx 96 well plates 
(QIAGEN) according to manufactures’ instructions. Briefly, the sequenced 
product was filtrated through a gel-like resin consisting of spheres with uniform 
pores that allow the dye terminators to diffuse, retaining them in the gel, while 
the DNA fragments are excluded and recovered in the flow-through. Finally, the 
samples were loaded on an ABI 3130xl Genetic Analyzer (Applied Biosystems).  
 
 
3.5. Cell culture and transfection 
The human neuroblastoma cell line SH-SY5Y (DSMZ) was cultured in a 
1:1 Dulbeco’s Modified Eagle Medium (DMEM)/F12 nutrient mixture (Ham) 
supplemented with 1% GlutaMAX™ I, 10% FBS and 1% Antibiotic-Antimycotic 
(all from Invitrogen) at 37ºC in a humidified 5% CO2 atmosphere. 
Cells were grown in 75 cm2 culture flaks (Sarstedt), and kept at a 
maximum 90% confluency, by trypsinization and subculturing. All replicas from 
a given experiment used cells from the same passage number, which never 
exceeded 5 passages.  
For subculturing, neuronal cells were detached by incubating them with 2 
mL of Trypsin-EDTA (0.25% Trypsin and 1 mM EDTA, Invitrogen) for 5 min at 
37ºC, which was neutralized by adding FBS containing medium. The cells were 
then re-suspended in fresh supplemented medium and cultured at 5x105 
cells/well, in 12-well plates (Nunc). For nitrogen storage, instead of plating cells, 
they were aliquoted in DMEM with 10% DMSO.  
Cells were transfected either 24h or 48h (coverslips) after plating, using 
FuGENE HD (Roche) following manufacturer’s instructions. The optimal ratio 
FuGENE:plasmid cDNA was determined as 3:1, and 75 µL of the resulting 
complex containing mixture, were used to transfect each condition. 
Calpain inhibition was achieved by co-transfection with calpastatin 
expression vector. Autophagy activation was accomplished by treatment with 
rapamycin. No dosage-response curve fit for determining rapamycin 
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concentration was performed, as it has previously been determined, for the 
same cell line, by others [65]. 
SH-SY5Y stably expressing mutant and wild-type PKCγ were also 
prepared. A T25 culture flask was transfected with each construct, as previously 
described, and 72h after transfection the culture medium was changed to 
culture medium containing 500 µg/mL of G418 (Invitrogen). The culture medium 
was renewed as needed and the cultures were maintained for six weeks, after 
which, they were subcultured without the selecting agent, and stored. 
 
 
3.6. RNA extraction 
Total RNA was isolated from transfected cells using the TRIzol Reagent 
(Invitrogen) as per manufacturer’s recommendations. Briefly, cells were lysed in 
500 µL of TRIzol and incubated for 5 min (room temperature), after which 100 
µL of chloroform were added, and vigorously mixed with each sample. 
Following a 3 min resting period, phases were separated by centrifugation at 
12000g, for 15 min (4ºC). The aqueous phase was recovered, and RNA was 
precipitated with 250 µL of isopropyl alcohol and pelleted by centrifugation 
(12000g, 10 min, 4ºC) after 10 min of room temperature incubation. The 
supernatant was discarded and the RNA pellet was washed with 500 µL of 75% 
ethanol. Samples were centrifuged again (7500g, 5 min, 4ºC), the RNA pellet 
was air dried and re-suspended in DEPC-treated water. Finally, samples were 
incubated at 50ºC, for 10 min, to allow solubilization, and stored at -80ºC.  
Total RNA quantification was performed using NanoDrop 2000 (Thermo 
Scientific) and RNA quality was assessed using QIAxcel (QIAGEN) and the 
RNA QC Kit v2.0 (QIAGEN), a gel cartridge for automated RNA capillary 
electrophoresis. 
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3.7. Real-Time PCR 
The SuperScript III first-strand synthesis system (Invitrogen) was used to 
generate total cDNA from 1 µg of total RNA of each sample. The standard 
oligo(dT)20 primer was used and manufacturer’s instructions were followed for 
the reverse transcriptase reaction.  
Real-time PCR was performed to measure PRKCG, CAST, and the 
housekeeping gene ACTB mRNA levels in transfected SH-SY5Y cells. The 
three genes were amplified with the iQ SYBR Green supermix (Bio-Rad) by 
adding to 1 µL of a ten-fold dilution of the cDNA synthesis reaction, 10 µL of 
SYBR Green supermix, 0.25 µL of the 10 µM specific primer (Table 3) and 
ddH2O up to a final volume of 20 µL. Amplifying conditions were as follows: an 
initial denaturing cycle at 95ºC for 3 min, followed by 40 cycles of denaturation 
at 94ºC for 30 sec, annealing at 57ºC for 30 sec, and an extension at 72ºC for 
30 sec, performed in an iQ5 Real-Time PCR detection system (Bio-Rad). Three 
replicas of the same sample per gene analysed we made, and the average Ct 
was determined. Data is presented as relative mRNA levels of the gene of 
interest normalized to relative levels of ACTB mRNA. 
 
Table 3 – Primers used for real-time quantification of ACTB, PRKCG and CAST mRNA 
levels. Note that each pair of primers is amplifying across exon-exon junctions assuring 
that the real-Time results are not due to genomic amplification.  
Gene Primer Amplicon size Tanneling 
ACTB 
   
Fw 5'-GCACTCTTCCAGCCTTCCTTC-3' 
Rv 5'-GTGATCTCCTTCTGCATCCTGTC-3' 176 bp 57 ºC 
PRKCG    
Fw 5'-CTCCACTCCACCTTCCAGAC-3' 
Rv 5'-CCTGTAGATGATGCCCTGATTG-3' 180 bp 57 ºC 
CAST    
Fw 5'-GTGTGGCTGGAGGTGGGACTGTG-3' 
Rv 5'-AGATGGCTTGCTCGGTGTGGACTG-3' 116 bp 57 ºC 
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3.8. Protein extracts 
Cells expressing target proteins were collected 24h, 48h and 72h after 
transfection. Briefly, cells were washed with warm HBSS (Invitrogen) and 
collected, on ice, in 75 µL of RIPA buffer (Sigma) supplemented with a 
cOmplete Protease Inhibitor Cocktail (Roche). Samples were sonicated and 
then centrifuged for 10 min at 13000 rpm. The soluble fraction was collected 
and total protein was measured with the DC Protein Assay (Bio-Rad) according 
to manufacturer’s instructions. Working aliquots of each sample were prepared 
in Laemmli buffer with 0.7% β-mercaptoethanol and denatured at 100ºC for 10 
min. 
 
 
3.9. Western blotting 
The samples were electrophoresed in a polyacrylamide 37.5:1 
(Acrylamide/Bis-acrylamide) denaturating gel, at 120 V in a mini-Protean 
system (Bio-Rad). The stacking concentration was kept at 4% and the running 
resolution varied according to the proteins being probed. The resolved proteins 
were afterwards transferred into an Immobilon-P PVDF membrane (Millipore) 
using semi-dry blotting at 38 mA, for the first hour, and at 76 mA, during the 
second hour, with transfer buffer (48 mM Tris-base, 39 mM glycine, 0.0375% 
SDS, 20% methanol). The membranes were blocked in a 3% non-fat powder 
milk (PM) PBS-T solution for 1h at 4ºC, and then incubated overnight with, 
mouse anti-PKCγ (3:1000) (Transduction laboratories), mouse anti-GFP 
(3:1000) (Abcam), mouse anti-FLAG (1:1000) (Sigma), rabbit anti-LC3 (1:1000) 
(Cell Signaling) and rabbit anti-TH (1:1000) (Cell Signaling) diluted in 3% PM 
(PBS-T). Mouse anti-β-actin (1:10000) (Sigma) was subsequently incubated for 
1h at 4ºC. 
Secondary, goat anti-mouse (Santa Cruz) and goat anti-rabit 
(Calbiochem), horseradish peroxidase-conjugated (HRP) IgGs, diluted 1:10000 
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in 3% PM PBS-T were incubated for 1h at 4ºC. Membranes were washed with 
PBS-T in between steps, and finally, their immunoreactivity was visualized, 
using the FemtoMax chemiluminescent Western blot kit (Rockland). Band 
quantification was performed on the GS-800 calibrated imaging densitometer 
(Bio-Rad). 
 
 
3.10. Immunofluorescence assays 
Acid washed 13mm coverslips were washed with 70% ethanol and 
rinsed with cell culture grade water. Afterwards, coverslips were incubated for 
one hour at 37ºC, with 400 µL of a 0.2 mg/mL Collagen type I solution 
(STEMCELL Technologies), and then air dried and washed again with sterile 
water. Cells were plated and left to adhere for 48 h, before handling.  
After 24h, 48h and 72h of treatment, cells were fixed with 4% 
formaldehyde, 4% sucrose in PBS for 20 min and permeabilized with 0.3% 
Triton-X100 in PBS for 15 min. Blocking was done with 10% FBS for 30 min at 
room temperature. Coverslips were incubated overnight at 4ºC with primary 
antibodies, mouse anti-FLAG (Sigma) and rabbit anti-LC3 (Cell Signaling), 
diluted 1:1000 in 5% FBS, 0.01% Triton-X100 (PBS). Secondary, goat anti-
mouse and anti-rabbit AlexaFluor 568 conjugated antibodies (Invitrogen), 
diluted 1:2000 in 5%FBS, 0.01% Triton-X100 (PBS) were incubated at room 
temperature for 40 min. Cells were stained with a 1 µg/mL solution of Hoechst 
33342 (Invitrogen) for 5 min. PBS was used to wash cells in-between all steps. 
The coverslips were then mounted in 5 µL of ProlongGOLD, allowed to dry and 
sealed with nail polish. The results were visualized in a wide-field fluorescence 
microscope – Axio Imager Z1 (Carl Zeiss). 
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3.11. Aggregate quantification 
Image analysis for aggregate quantification was performed using open 
source ImageJ. The 12 bit images were converted to 8 bit and a ten-pixel 
background was subtracted to the GFP channel. Afterwards a median filter with 
a one-pixel matrix was applied and the default threshold was determined. The 
number of particles per cell was analyzed by counting the area of every particle 
with 0.01 µm2 and higher, which allowed the exclusion of single pixels.  
 
 
3.12. Cell viability assay 
In order to assess cell viability, the CellTiter-Glo cell viability assay kit 
(Promega) was used. This kit is based on the luciferase reaction and directly 
correlates cell viability with the total amount of ATP present in each sample. 
SH-SY5Y cells were cultured in opaque-walled 96-well plates, at 39,5x103 
cells/well in a total volume of 100 µL, and then transfected as previously 
described. After different time periods, an equal volume of CellTiter-Glo reagent 
was added to the culture medium present in each well (100 µL) and the plate 
contents were mixed on an orbital shaker for 2 min. The plate was allowed to 
incubate at room temperature for 10 min and luminescent signal was measured 
in a Synergy 2 SL Luminescence Microplate Reader (BioTek). 
 
 
3.13. Statistical analysis 
Cell viability, RNA expression and aggregate quantification data are 
expressed as mean ± SEM. Comparison of calpastatin and rapamycin effect on 
the studied mutants was done using one-way or two-way ANOVA with a 
Bonferroni post-hoc test for multiple comparisons. Number of cells with and 
without aggregates was compared between wild-type and mutant cells using 
the χ2 test. The mean number of aggregates in wild-type and mutant cells was 
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compared by Student’s unpaired t-test. Differences were considered to be 
significant when p<0.05. Statistical analysis was performed using PASW 
Statistics 18. 
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4. Results 
During this project we have created and characterized cellular models 
overexpressing mutant PKCγ with eight different mutations found in patients 
with spinocerebellar ataxia type 14. We have selected mutations located in 
different PKCγ domains in order to have a broader insight into the effect of the 
diverse mutations. We were able to demonstrate the existence of two different 
groups of GFP-positive cells showing high and low PKCγ expression. Our data 
show that the different studied mutation do not have an impact on cell viability, 
although resulted in differences in the number of cells showing PKCγ 
aggregates and in the number of aggregates present in each cell. We were also 
able to show that inhibition of PKCγ by calpain has as impact both in cell 
viability and in aggregate formation, resulting in increased viability and 
reduction of aggregate formation in cells with inhibited calpain function. 
Similarly, autophagy activation also results in increased cell viability and 
reduction of aggregate levels. Moreover, our data allows us to propose that 
PKCγ may be a CMA substrate. Finally, during this thesis project we have 
created SH-SY5Y transgenic cell lines permanently expressing wild-type and 
mutant PKCγ that will allow further exploring the mechanisms involved in 
SCA14 pathogenesis. 
 
 
4.1. PKCγ wild-type and mutant cell line characterization 
In order to perform a full characterization of the obtained cell lines, PKCγ 
expression was assessed at the protein level through florescence microscopy 
and western-blot, and at the RNA level through real-time PCR. The impact of 
wild-type and mutant PKCγ expression on cell survival was also assessed as 
well as aggregate formation characterization. 	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4.1.1. PKCγ expression in SH-SY5Y cells 
Neuroblastoma cells are usually difficult to transfect, nonetheless, we 
have optimized the transfection protocol up to an estimated transfection 
efficiency of ~95%. 
Analysis of transfected cells under an optic fluorescence microscope 
allowed us to identify two groups among the GFP positive cells, one with high 
GFP fluorescence and another with low GFP as shown in Figure 6 for the wild-
type PKCγ. The lower panel of this figure shows the relative abundance of the 
two types, so that high expression cells account for about 30% of the cell 
culture.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 6 – Representative images of wild-type GFP-PKCγ expressing cells. The 
transfected culture has two groups of cells, high GFP and low GFP (upper panel); 
scale bar: 10µm. Lower panel shows the relative amounts of high and low expressing 
GFP cells. The cell nucleus is counterstained with Hoechst 342. Scale bar: 100µm.  
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Quantitative analysis of GFP-PKCγ protein levels, by western-blot, in SH-
SY5Y cells has been a challenging task, with often-inconsistent results, that will 
warrant further scrutiny in the future, and thus are not shown here. 
Nevertheless, the same experiment was reproduced in HEK-293 cells, and the 
resulting immunoblot of protein extracts collected 48h after transfection is 
shown in figure 7. Quantitative analysis of the obtained immunoblot was 
performed and relative expression towards GFP-PKCγ shows a marked 
decrease of soluble protein in the majority of the mutants. 
 
 
 
  
 
 
 
 
 
 
 
Figure 7 – Quantitative analysis by western-blot of soluble wild-type and mutant PKCγ 
protein levels in HEK-293 cells, 48h after transfection, using an anti-PKCγ antibody 
(upper panel). Representation of one experiment is shown, and data is expressed as a 
percentage of GFP-PKCγ (lower panel). 
 
Quantitative analysis of PKCγ expression in our model system was 
performed, and PRKCG mRNA expression was normalized towards ACTB 
levels. Total mRNA was extracted at 24h, 48h and 72h after transfection, cDNA 
was synthesized and real-time PCR was optimized to 100% efficiency. The 
mRNA expression results of three independent experiments are represented in 
Figure 8, showing that relative expression of normal and all mutant PKCγ do not 
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significantly differ at each time point. Thus, we can infer that transfection 
efficiency of the different construct does not present significant variation 
allowing us to proceed with mutants’ characterization and comparison. 
 
  
 
 
 
 
 
 
 
Figure 8 – Quantitative analysis of PKCγ mRNA levels at three time points after 
transfection. Data is shown normalized towards β-actin. Means ±SEM of three 
independent experiments are shown.  
 
 
 
4.1.2. Cell survival in wild-type and mutant PKCγ cell lines 
In order to assess cell viability in the presence of wild-type and of the 
different mutant PKCγ over-expression we have used the CellTiter-Glo kit that 
correlates total ATP with the amount of viable cells. In Figure 9 we present the 
results of three independent experiments regarding cell survival at 24h, 48h and 
72h after tranfection. Our results show that the different PKCγ mutants do not 
have a significant impact on cell viability at each time point, or between the 
three time points. 
 
 
	   34	  
 
 
 
 
 
 
 
 
 
Figure 9 - Cell viability of SH-SY5Y cells at three time points after transfection with 
wild-type and mutant GFP-PKCγ. Means ±SEM of three independent experiments are 
shown. 
 
 
 
4.1.3. Wild-type and mutant PKCγ aggregate formation 
Mutant protein aggregation is a common hallmark in several 
neurodegenerative disorders. In order to explore aggregate formation of mutant 
PKCγ, fluorescence imaging was carried out with coverslips from three 
independent experiments (raw data was acquired) and aggregate quantification 
was performed. Data shown in Figure 10 reflect the results for one the 
experiments, where the total numbers of cells analyzed are depicted, as well as 
the relative numbers of cells with or without aggregates, for each condition, at 
24h, 48h and 72h after transfection. In our model system, at a given time point 
only some of the mutants showed statistically significant differences from the 
wild-type form. Furthermore, normal PKCγ showed a considerable amount of 
aggregation, notwithstanding that we are using an over-expressing system 
where the overall expression level is not too high, as we have seen before.  
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Figure 10 – Quantitative analysis of 
aggregate formation of wild-type and 
mutant PKCγ in SH-SY5Y at 24h (A), 
48h (B) and 72h (C) after 
transfection. Comparison between 
mutant versus PKCγ aggregation. 
Representation of one experiment is 
shown. *P<0.05; **P<0.001. 
 
 
The H101Y mutation showed more aggregation 24h post transfection 
(P=0.017) as well as F643L (P<0.001), whereas at 48h more protein 
aggregation was seen for S361G (P=0.047) and F643L (P=0.005). At 72h, four 
mutants showed significant differences: C131R (P=0.021), S361G (P=0.004), 
F643L (P=0.005) and V692G (P=0.024). Taken together, only one mutant 
(F643L) was consistent in showing more aggregation at all three time points.  
Regarding the mean number of aggregates per cell with PKCγ 
aggregation (Figure 11), some statistical differences were found between wild-
type and mutant PKCγ at 48h and 72h. At 48h post transfection, G63V 
(P=0.018), H101Q (P=0.033), H101Y (P=0.008) and C131R (P=0.007) 
presented a larger number of aggregates per cell than normal PKCγ, while at 
72h only C131R (P=0.010) and F643L (P<0.005) had significantly more 
aggregates than PKCγ. 
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Figure 11 – Mean number of aggregates per cell containing aggregation, at three time 
points post transfection, regarding each mutant. Means ±SEM of one experiment is 
shown. *P<0.05 
 
As for cellular distribution of aggregates, no particular predilection for any 
intracellular location was observed, though when cells presented one to two 
aggregates they often were perinuclear.  
Representative images of PKCγ aggregation are displayed in Figure 12, 
randomly selected from each condition at a given time point. 
 
 
 
 
 
 
 
 
Figure 12 – Representative images of wild-type and mutant GFP-PKCγ aggregation in 
SH-SY5Y cells at three time points after transfection. The cell nucleus is 
counterstained with Hoechst 342. Scale bar: 10µm. (next two pages) 
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4.2. Calpain cleavage: influence on pathogenesis 
Calpain-mediated proteolysis has been implicated in some 
neurodegenerative disorders. Aiming to assess the role of PKCγ cleavage in 
SCA14, we explored the effect of calpain inhibition by calpastatin expression on 
cell survival and aggregate formation. 
 
4.2.1. Calpastatin expression levels 
In order to assess co-transfection efficiency, PRKCG and CAST mRNA 
levels were quantified through real-time PCR and their expression was 
normalized towards ACTB. Quantitative analysis results of three independent 
experiments are presented in Figure 13. Here we can see that co-transfection 
with calpastatin yielded very similar amounts of PRKCG and CAST in each 
condition, and statistically indistinguishable levels amongst normal and mutant 
PKCγ at every time point.  
 
 
 
 
 
 
 
 
 
Figure 13 - Quantitative analysis of 
PKCγ and calpastatin mRNA levels at 
three time points after tranfection. 
Comparison beween PKCγ transfection, 
and calpastatin co-transfection. Data is 
shown normalized towards β-actin. 
Means ±SEM of three independent 
experiments are shown.  
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However, comparison with SH-SY5Y cells transfected only with PKCγ 
show some statistical differences (not indicated) with a tendency for an increase 
of expression levels in the co-transfection case.  
 
 
4.2.2. Impact of calpastatin expression in cell survival 
Cell viability was assessed after co-tranfection with calpastatin and the 
results of three independent experiments for 24h, 48h and 72h post transfection 
are shown in Figure 14. In line with what we have seen before regarding the 
mutant behavior versus wild-type PKCγ, inhibiting calpain cleavage through co-
transfection with calpastatin did not affect the mutant viability when compared to 
normal PKCγ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 – Cell viability of SH-SY5Y 
cells at 24h (A), 48h(B) and 72h(C) 
after tranfection. Comparison beween 
transfection and co-transfection with 
calpastatin. Means ±SEM of three 
independent experiments are shown. 
*P<0.05; **P<0.001. 
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Nevertheless, significant results were obtained regarding calpain 
inhibition in general, with a slight increase in cell viability at 24h post 
transfection and a progressive increase in cell viability until 72h. Additionally, 
cell viability in the presence of calpastatin is very similar to that of non-
transfected cells at every time point. 
 
 
4.2.4. Impact of calpastatin in aggregation formation 
Calpastatin effect on aggregate formation was carried out by 
fluorescence imaging of coverslips. Three independent experiments were 
carried out for calpain inhibition through calpastatin co-transfection. Results for 
one the experiments are shown in Figure 15 where the total numbers of cells 
analyzed are depicted, as well as the relative numbers of cells with or without 
aggregates, for each condition, 24h, 48h and 72h after co-transfection.  
 
 
 
 
 
 
 
 
 
 
Figure 15 - Quantitative analysis of 
aggregate formation of wild-type and 
mutant PKCγ in SH-SY5Y when they 
are co-transfected with calpastatin, at 
24h (A), 48h (B) and 72h (C) after 
transfection.  
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Overall, at any given time point no statistical differences were found, 
either amongst wild-type and mutant PKCγ, or between the number of hours 
post transfection. Conversely the presence of calpastatin alone was enough to 
drastically reduce the percentage of aggregation in all cases, at 24h (P=0.001), 
at 48h (P=0.001) and especially at 72h (P<0.001). 
Immunocytochemistry was done to probe for calpastatin (FLAG-tagged), 
however our protocol is not, yet sufficiently optimized and unspecific binding 
was still observed in the control coverslip and thus these data are not 
presented. 
We also plotted the mean number of aggregates that each cell contained 
(Figure 16), which revealed no statistically significant differences either between 
mutants or wild-type PKCγ versus mutants at any transfection time. However, 
when we compare the data in Figure 11 (from PKCγ transfection alone) to 
Figure 16 (calpastatin co-transfection), regarding the mean number of 
aggregates per cell, in the majority of the cases there are statistically significant 
differences between the presence or absence or calpastatin, at every time point 
– for almost all cases in the presence of calpastatin there are less aggregates 
per cell. 
 
 
 
 
 
 
 
 
Figure 16 – Mean number of aggregates per cell containing aggregates, at three time 
points post co-transfection with calpastatin, regarding each mutant. Means ±SEM of 
one experiment is shown. 
	   43	  
W
T 
H1
01
Q 
G6
3V
 
H1
01
Y 
C1
31
R 
S3
61
G 
F6
43
L 
V6
92
G 
R4
1P
 
42- 
kDa 
!-actin 
LC3-I 
LC3-II 
16- 
14- 
0.2 µM Rapamycin 
Co
nt
ro
l 
4.3. Activation of the macroautophagy pathway 
Autophagy has been largely associated with protein aggregate clearance 
in neurodegenerative disorders. In order to explore the autophagic process in 
SCA14 we have treated wild-type and mutant PKCγ cell lines with rapamycin, 
an autophagy inducer. Transfected SH-SY5Y cells were treated during the last 
48h with 0.2µM rapamycin and the resulting cellular extracts were 
electrophoresed and probed with anti-LC3 antibody in order to assess 
macroautophagy activation. Immunoblot of cells treated with rapamycin shows 
bands corresponding to LC3-I and LC3-II indicating LC3 activation when 
compared with untreated cells (Control – untreated, untransfected SH-SY5Y 
cells) (Figure 17). Results for only one experiment are shown and thus no 
quantification of LC3 activation is presented.    
 
 
 
 
 
 
 
Figure 17 – Western-blot of wild-type and mutant PKCγ SH-SY5Y transfected cells, 
treated with 0.2µM rapamycin for 48h (24h after transfection), using an anti-LC3 
antibody. 
 
 
4.3.1. Impact of rapamycin in cell survival 
Transfected SH-SY5Y cells were treated during the last 48h with 0.2µM 
rapamycin and their cell viability was measured. The vehicle (DMSO) was used 
as a control and proved not to decrease cell viability (data not shown). As we 
have shown before for calpain inhibition, treating cells with rapamycin did not 
significantly alter the behavior of any particular mutant regarding cell survival. 
Though treatment with rapamycin alone, proved to significantly increase cell 
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viability in all conditions (P=0.003). Although not shown in Figure 18, rapamycin 
treatment of transfected cells increased survival to levels observed in 
untransfected and untreated SH-SY5Y cells, while equal treatment with 
rapamycin, of untransfected SH-SY5Y cells by itself was enough to increase 
their viability by ~25%, after 72h in culture. 
 
 
 
 
 
 
 
 
Figure 18 - Cell viability of SH-SY5Y cells at 72h after transfection. Comparison 
between transfection alone and treatment of transfected cells with rapamycin (0.2 µM) 
for 48h (24h after transfection). Means ±SEM of three independent experiments are 
shown. *P<0.05. 
 
 
 
4.3.2. Effect of rapamycin in aggregate formation 
The same treatment as described above for cell viability was applied to 
SH-SY5Y cells, previously adhered to coverslips. Three independent 
experiments were carried out and raw data was acquired for one of them using 
fluorescence microscopy. However, the processed coverslips were not of 
sufficient quality for proper analysis, and therefore we were not able to include 
any result of aggregate quantification, at this point in time. 
Immunocytochemistry was also done to probe for LC3, but unspecific binding 
was still observed in the control coverslip, and thus these data are not shown. 
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In spite of this, some general considerations regarding what was 
observed can be made. In particular, high GFP expressing cells were mostly 
apoptotic at 72h while low expressing cells seamed mostly healthy (even if they 
contained aggregates). An example of this is shown in Figure 19 concerning the 
R41P mutant. Although we are only showing images for this mutant the same 
observation was made in all other conditions, including wild-type PKCγ. 
 
 
 
 
 
 
 
Figure 19 – Representative images of the GFP-R41P PKCγ mutant after treatment 
with 0.2µM rapamycin. The two groups of cells, high GFP and low GFP are shown. The 
cell nucleus is counterstained with Hoechst 342. Scale bar: 10µm.  
 
 
 
4.4. PKCγ: a possible CMA substrate 
 Given our interest in autophagy, we wanted to investigate whether PKCγ 
could be a CMA substrate; in order to see if there were strong enough clues to 
pursue this line of thought with in vitro studies. 
 Through analysis of the human PKCγ sequence (NP_002730.1) we 
found several KFERQ-like motifs highlighted in Figure 20, more specifically, one 
conventional (a.a. 162-166), two non-conventional (a. a. 481-485; 642-646) 
along with other imperfect motifs. Molecular modelling with visual molecular 
dynamics (VMD) [66] of the available crystallographic structure of the C2 
domain of PKCγ (PDBID:2UZP) and highly homologous conventional PKCβII 
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(PDBID:2I0E) allowed us to determine that among the motifs previously 
identified the second non-conventional NFDKF (a. a. 642-646) is more surface 
exposed and if indeed PKCγ is a CMA substrate, this motif is the most probable 
to target its degradation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 – Amino acid sequence of Protein kinase C γ. After sequence analysis, the 
yellow box identifies the conventional KFERQ motif; non-conventional KFERQs are 
depicted in green and imperfect motifs are underlined. 
 
 
 
4.5. SH-SY5Y transgenic wild-type and mutant PKCγ cell lines 
 Although transient transfection revealed to be surprisingly efficient for 
these cells and constructs, it requires high cell density in order to work properly. 
High quality microscopy imaging is, however, harder to achieve if cells are 
overpopulating the coverslip. Therefore, establishing cell lines permanently 
expressing GFP-PKCγ and mutants rapidly became one of this project’s 
objectives. Transgenic SH-SY5Y cell line for wild-type GFP-PKCγ is shown in 
Figure 21 as an example of success in achieving this goal, and furthermore 
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demonstrates that the cell culture characteristics have been maintained, with a 
mix of high and low GFP expressing cells. 
 
 
 
 
 
 
 
Figure 21 - Representative images of wild-type GFP-PKCγ expressing cells in the 
stably transfected SH-SY5Y cell line. The cell nucleus is counterstained with Hoechst 
342. The culture presents two groups of cells, high GFP and low GFP, similarly to the 
transient transfection. Scale bar: 10µm.   
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5. Discussion 
5.1. PKC gamma aggregation 
Besides the neurodegenerative pattern, the other most notorious 
common thread between spinocerebellar ataxias is perhaps the formation of 
inclusions or aggregates [67]. Here, we selected eight PKCγ mutants to study, 
covering all domains of this protein kinase. Furthermore, since the 101 histidine 
is the most recurrently mutated residue in SCA14, we included two substitutions 
at this amino acid position [68]. 
It has been shown that mutations in the PRKCG gene, responsible for 
SCA14 and encoding an altered PKCγ, have the ability to form different types of 
aggregates. In particular, a group of authors has shown this aggregating feature 
in various heterogeneous expression systems: CHO, COS-7, HeLa, HEK-293, 
SH-SY5Y and primary Purkinje cells [16,18,19,65,69,70]. According to them, 
three major classes of aggregates could be found: dot-like, medium-size and 
massive aggregates; however, our expression system in SH-SY5Y cells was 
not able to reproduce these findings. Almost all cells presenting aggregates had 
dot-like inclusions, and only very few of them bared medium-sized aggregates. 
Furthermore, the most striking difference in our findings was the absence of 
massive aggregation in the whole amount of raw data acquired regarding 
fluorescence imaging (~6000 cells), only one massive aggregate was found in a 
cell with the V692G mutant (40 µm2), 24h after transfection. Likewise, Verbeek 
and colleagues have not observed massive aggregation when they expressed 
wild type or mutant PKCγ in COS-7 and HeLa cells [71]. 
Against what has been described before [16], the ability of mutant GFP-
PKCγ to form aggregates did not consistently vary from that of wild-type PKCγ, 
though all studies involving functional analysis of a considerable number of 
mutations did not use neuronal cells [16,19]. In our study, the percentage of 
cells/neuroblastomas with wild-type GFP-PKCγ aggregates was higher than the 
20% (or less) previously reported for non-neuronal cells [16,19,69], thus, one 
could argue that this is due to over expression, but only about 30% of the 
transfected cells brightly express GFP-PKCγ. On the other hand, this could also 
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be a reflection of wild-type GFP-PKCγ intrinsic propensity for aggregation. 
Native PAGEs of Purkinje cell extract have shown that normal PKCγ-GFP might 
occur in dimers and monomers, while mutant forms, form soluble higher order 
oligomers [18]. In fact, the well-established PKC life cycle presented in Figure 2, 
already hints towards this. After activation (in the open conformation), PKCs are 
highly susceptible to phosphatases, and once dephosphorylated, in the 
absence HSP70, they easily become insoluble [36]. 
Like others have seen before, we have two populations of transfected 
cells, high and low GFP expressing, and similarly there is a correlation between 
expression level and cell death [16]. Cultured cells expressing high levels of 
wild-type or mutant PKCγ tend to die more quickly, with apoptotic nuclei, and 
low expression cells tend to survive longer. 
Conversely, in the cell viability assay, we did not see any differences 
between wild-type and mutant PKCγ, or even a tendency for a decrease in cell 
viability after 72h of constructs expression. Regarding this, and taking into 
account our observations during all cell manipulations, we believe that high 
GFP expressing cells are dying quickly mainly before 24h, and low expressing 
cells are behaving more closely to healthy cells, even though a considerable 
amount bear aggregates. Here, maybe the time frame in which we are looking 
at cell survival after construct expression needs to be adjusted either for a 
shorter period then 24h as well as longer than 72h. 
Overall when comparing our results to that of other groups, we find one 
striking difference that could account for the major inconsistencies we observed 
- in all other studies the GFP tag was in the PKCγ C-terminal while ours was N-
terminally positioned (Table 4). This, to hold true, could mean that the N-
terminal tag is somehow preventing aggregation, since massive inclusions have 
been seen in untagged PKCγ mutants [16]. Furthermore, it could also indicate 
that the N-terminal domain is the one primarily responsible for aggregation. In 
fact, about 80% of the mutations found in the PRKCG gene are located in the 
regulatory portion of PKCγ, specifically in the C1 domain [68]. Surprisingly so, 
mutations in the Ca2+ binding, C2 domain of PKCγ have never been found in 
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SCA14 patients. It would be interesting to create a C2Δ-PKCγ and see if it also 
relates to SCA14 pathogenesis or is otherwise incompatible with life, and 
therefore has never been found before. To further clarify whether having an N-
teminus tag is in fact different from a C-terminal one, we are currently working 
on building an untagged PKCγ construct as well as a pEGFP-N1-PKCγ. 
 One aspect that should be taken into account is the post-mortem 
analysis of brains from SCA14 patients. Immunohistochemistry using an anti-
PKCγ antibody detected no aggregates or inclusions in slices of these patients’ 
brains, although one must admit they were very few and all were carriers of the 
H101Y mutation [10]. Once again, over expression could account for these 
discrepancies. It would be interesting to measure PKCγ expression in primary 
cultured Purkinje cell and compare it to expression in our system. 
 
Table 4 – Summary of the SCA14 cellular models described. All models except ours 
have a C-terminal GFP tag. 
Tranfection 
method Vehicle Cell type Reference 
pEGFP-C1-PKCγ SH-SY5Y Our study 
pEGFP-N1-PKCγ COS-7/HeLa [9] [71] 
?-PKCγ-GFP COS-7/HeLa/ CHO/HEK-293 [19] 
Lipofection 
pcDNA3 (PKCγ-GFP) CHO [16] [69] 
L7-tTA (PKCγ-GFP) Primary mouse PCs [18] 
Adenoviral 
CMV-tTA (PKCγ-GFP) SH-SY5Y/Primary mouse PCs [65] 
 
 
PKCγ intervenes in several cellular processes, and a myriad of proteins 
have been found to be subject of phosphorylation by this kinase. Among them 
the metabotropic glutamate receptor 5, non-muscle myosin heavy chain II-B, 
myristoylated alanine-rich C kinase substrate (MARCKS), GSP43/B-50, HMG-I, 
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RC3/neurogranin and glycogen synthetase, aprataxin stands out, as it was 
found to be a preferential substrate of mutant PKCγ [72]. When mutated, 
aprataxin is also the cause of a recessive form of ataxia – ataxia with 
oculomotor apraxia type 1 (AOA1). This myriad of interactors (largely unknown 
yet) gives rise to the hypothesis that when mutated, PKCγ might favor some 
interactions in detriment of others as it happens with ataxin-3, responsible for 
Machado-Joseph disease/SCA3 [73]. The differential distribution of key proteins 
expressed by individual cells from the same type, may also contribute to the 
selective loss of some neurons [74].   
Very recently, the efficient generation of human induced neuronal cells 
(hiN) from skin fibroblasts was reported [75,76]. The authors were able to 
reprogram skin cells into neurons with the correct electrophysiological 
properties, and the ability to integrate a neuronal circuitry in vitro and in vivo. 
Moreover, they show the successful conversion of skin fibroblasts from 
Alzheimer’s patients carrying PSEN mutations into neuronal cells, displaying 
characteristics consistent with the brain pathology and remaining literature 
about presenilins [75]. The possibility of creating a model system for SCA14, as 
well as other neurodegenerative disorders, more closely related to the native 
environment of neuronal cells in patients is now much closer, and could be the 
answer, given all the controversial results regarding mutant PKCγ. 
  
5.2. Calpain inhibition in SCA14 
Calpains are believed to participate in various biological processes, 
including integrin-mediated cell migration, cytoskeletal remodeling, cell 
differentiation and apoptosis [47]. Also, toxicity by calpain activity has been 
associated with a broad number of neurodegenerative diseases, including 
Huntinton’s and Parkinson’s, extensively reviewed by Volsler et al (2008) [48].  
PKCγ is amongst the long list of calpain substrates already identified, it 
possesses two cleavage sites, for either m- or µ-calpains, located at the V3 
hinge region – after serine 321 and phenylalanine 338. The V3 hinge connects 
the regulatory to the kinase domains; consequently, cleavage at this site gives 
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rise to a permanently active kinase fragment, no longer dependent on Ca2+ and 
phospholipid binding [49]. Given this, we wanted to investigate whether 
proteolytic cleavage of PKCγ was influencing SCA14 pathogenesis. By 
expressing the natural calpain inhibitor, calpastatin, we show that its presence 
alone, in a 1:1 ratio to PKCγ, is enough to significantly reduce aggregate 
formation and increase cell survival. Unfortunately we were not able to detect 
cleavage fragments through western-blot, and therefore we can only infer about 
the prevention of PKCγ proteolysis. Calpain involvement in initiating an 
apoptotic cascade after an apoptotic stimulus is well documented, and the 
outcome we see from calpastatin co-trasfection, could also be due to inhibition 
of this ability [77], where, overexpression of PKCγ could represent the apoptotic 
stimulus. This ameliorating effect of calpastatin, however, is clearly not acting 
by decreasing PKCγ mRNA expression.  
Besides calpastatin, several classes of inhibitors, including peptidyl 
epoxide, aldehyde, and ketoamide inhibitors, targeting the active site of 
calpains have proven effective, however, a major limitation to the researcher is 
their lack of specificity among cysteine proteases and other proteolytic enzymes 
[78]. 
Another explanation for the calpastatin effect observed can be put 
forward, since calpastatin has also been recently described as an mTOR 
independent autophagy inducer. Calpains cleave Atg5, compromising its ability 
to participate in the double membrane elongation, and triggering apoptotic cell 
death. It has been shown that several drugs acting at various levels in this 
pathway (described in detail by Williams et al, 2008) can induce autophagy, 
including calpastatin [79]. Presenting, in theory, numerous new ways of 
increasing cellular autophagy levels. 
Taken together, our data and the recently described calpain role in 
autophagy provide novel avenues for further investigation of the impact of 
calpain-mediated proteolysis in neurodegeneration. 
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5.3. Autophagy activation and aggregate clearance 
In neurons, constitutive autophagy is essential in the maintenance of 
cellular homeostasis, and besides being an age-dependent cellular activity, it 
has also been found to be impaired in a number of neurodegenerative 
conditions [3]. 
Rapamycin inhibits the activity of mTOR (mammalian target of 
rapamycin), a kinase located in the core of two multiprotein complexes, 
mTORC1 and mTORC2, that are involved in a myriad of cellular processes, 
including protein synthesis, cell growth and proliferation as well as autophagy, 
which is induced in the presence of rapamycin. Treatment with this drug has 
proven to be beneficial in experimental models of several neurodegenerative 
diseases, such as Parkinson’s disease. Moreover, rapamycin is an FDA-
approved drug used as an antibiotic and immunosuppressor, and more 
recently, it started to be used in the treatment of cardiovascular diseases, thus 
representing a very attractive way of modifying neurodegenerative disease 
course [80]. 
For our SCA14 model, rapamycin treatment significantly increased 
survival of cells transfected with wild-type and mutant PKCγ. Nevertheless, the 
two types of GFP expressing cells were observed to have different behavior 
regarding cell viability in these conditions. High GFP expressing cells 
apparently were not rescued after drug treatment during 48h, as they were 
mostly apoptotic. For this sub-population, perhaps treatment after 24h of 
overexpression was tardy. Low GFP expressing cells were otherwise observed 
to behave like healthy cells although many still showed aggregates. Rapamycin 
action in our expression system still needs further analysis, in particular 
immunoblot quantification of soluble PKCγ and confirmation of autophagy 
activation through LC3 quantification.  
The newly generated permanently expressing PKCγ cell lines will be 
valuable tools for clarifying some of the obtained results and will also allow to 
perform live cell imaging to better understand the aggregate formation and cell 
death dynamics in our expression system.	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5.3.1. Protein kinase C gamma as a possible substrate for 
CMA 
A growing body of evidence supports a critical role for protein 
degradation machinery in neurodegeneration. CMA abnormalities have been 
tightly connected to Parkinson’s disease; in particular α-synuclein stands out 
and is perhaps the “golden example” of CMA failure in neurodegeneration [81]. 
Other diseases have also been linked to CMA, like polyglutamine disorders 
(Huntingnton’s and SCA7) and Alzheimer’s (Tau and APP) [82,83,84,85]. This 
research bottom-line suggests that mutant proteins either “clog” the lysosomal 
pore, interact abnormally with CMA machinery or disrupt the lysosomal 
membrane, compromising its and/or other CMA substrates degradation. 
Given this preponderant role CMA has gained in the last few years, to try 
and assess CMA function in SCA14 would be interesting. Our preliminary 
results indicate that PKCγ is a potential CMA substrate worthwhile of further 
investigation. Here, the transgenic SH-SY5Y cell lines we now have available 
will help us to further explore this subject; starting with the wild-type PKCγ 
transgenic for some assays such as serum starvation over 8h, proteasome, 
macroautophagy and CMA blockage, while following PKCγ accumulation.  
Curiously, the F643L mutant was the one that presented more consistent 
results and stood out from the remaining mutants, could it be just a coincidence 
that this mutation sits right in the middle of the KFERQ motif we deemed the 
most probable to target PKCγ for CMA degradation, even though it does not 
abolishes the motif?  
Furthermore, very recently a new method for tracking CMA degradation 
based on a photoconvertible fluorescent reporter was described, which we plan 
to use to assess the putative KFERQs we found, with the added advantage that 
the assay has already been validated for SH-SY5Y cells [86].  
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6. Conclusions 
The main aims proposed at the beginning of this thesis’ work were 
accomplished. A cellular model for spinocerebellar ataxia type 14 was 
successfully created, through efficient transient expression of both wild-type 
and mutant PKCγ, and validated through mRNA expression and fluorescence 
microscopy. Stable expression of these constructs was also achieved, providing 
a good platform for future confirmation of the obtained results and to further 
explore the mechanisms involved in SCA14 aggregate formation and clearance. 
We have demonstrated for the first time that calpain inhibition significantly 
reduces aggregate formation and increases cell survival in all experimental 
conditions, pointing to a role of PKCγ proteolysis in protein turn-over and 
aggregation. We were also able to show that rapamycin treatment also 
increased cell viability, including that of mutant PKCγ expressing cells. Our 
preliminary data also point for a wide role of rapamycin in aggregate clearance. 
The possibility of both these ameliorating effects being mediated and converge 
in autophagy activation is discussed, as well as the importance of the C1 
regulatory domain for PKCγ aggregation. We also provide evidence that PKCγ 
may be a target for CMA degradation. 
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7. Perspectives 
In light of our results, it will be important to clarify the influence of the tag 
on aggregate formation either regarding its presence, with an untagged 
construct, or its relative position to PKCγ, with pEGFP-N1-PKCγ. 
 SH-SY5Y cells expressing mutant PKCγ, did not show differences from 
wild-type in the assay used to infer cell viability, however, cell death was 
observed by fluorescence microscopy, and therefore, other methodology will 
have to be used in order to clarify mutant PKCγ impact in cell survival. 
 Live cell imaging of the transgenic cell lines generated will allow the 
observation of aggregate formation and dynamics, which will help to adjust the 
time-window we are using. 
 The time frame in which we are taking snapshots of our model system 
will most likely have to be expanded, since we want to collect information about 
the cells that have already died by 24h of overexpression, as well as follow 
aggregation and cell death in low GFP expressing cells beyond 72h.  
 Concerning calpastatin co-transfection, we would like to see if there are 
traces of macroautophagy induction, by quantifying LC3I/II levels through 
immunoblotting. Aggregate reduction/clearance through calpain inhibition, will 
additionally be confirmed by treatment of transgenic cell lines wild calpeptin, a 
cell permeable peptide derived from calpastatin, as well as one of the 
pharmacological drugs described by Williams et al (2008) as mTOR 
independent autophagy inducers, acting over the camp loop, to confirm or not 
the involvement of this pathway. 
 The experiments with rapamycin will be reproduced in the transgenic cell 
lines, in order to obtain clearer results. 
 The possibility of PKCγ being a CMA substrate will be further explored, 
by assessing the ability of each putative KFERQ to target a photoconvertible 
reporter for lysosomal degradation. We will also use the transgenic cell lines 
follow PKCγ accumulation in particular conditions (starvation, systematic 
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blockage of each degradation system), paying special attention to the F643L 
mutant. 
  We will also further characterize our experimental model by 
immunobloting PKCγ levels present in all experimental settings, in both soluble 
and insoluble fractions. 
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